Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- Amondys 45 (casimersen)
- Cuvrior (trientine)
Interactions between your drugs
No drug ⬌ drug interactions were found between the drugs in your list. However, this does not necessarily mean no drug interactions exist. Always consult your healthcare provider.
Drug and food/lifestyle interactions
trientine food/lifestyle
Applies to: Cuvrior (trientine)
ADJUST DOSING INTERVAL: The gastrointestinal absorption of trientine may be decreased in the presence of food, resulting in reduced therapeutic effects.
MANAGEMENT: Trientine should be administered on an empty stomach, at least one hour before or two hours after meals and at least one hour apart from any other food, drug, or milk.
References (1)
- (2001) "Product Information. Syprine (trientine)." Aton Pharma
trientine food/lifestyle
Applies to: Cuvrior (trientine)
GENERALLY AVOID: Concurrent oral administration of mineral supplements or mineral-containing products may block the absorption of trientine, and vice versa. The mechanism is trientine chelation of polyvalent metal ions resulting in a nonabsorbable complex.
MANAGEMENT: In general, mineral supplements or mineral-containing products (e.g., antacids) should not be used in patients treated with trientine. If concomitant use is unavoidable, separation of administration times by at least two hours is advisable.
References (3)
- (2001) "Product Information. Syprine (trientine)." Aton Pharma
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Vyondys 53
Vyondys 53 is used for Duchenne muscular dystrophy (DMD) in children and young adults with a ...
Exondys 51
Exondys 51 is used for Duchenne Muscular Dystrophy (DMD) in children and young adults with a ...
Elevidys
Elevidys is a gene therapy for Duchenne muscular dystrophy, that is given as a one-time infusion ...
Duvyzat
Duvyzat (givinostat) is used to treat Duchenne muscular dystrophy (DMD) to delay symptoms and ...
Agamree
Agamree (vamorolone) is an FDA-approved treatment for Duchenne muscular dystrophy (DMD) to improve ...
Emflaza
Emflaza (deflazacort) is a corticosteroid medication used to treat a rare genetic disorder called ...
Viltepso
Viltepso (viltolarsen) is used for the treatment of Duchenne muscular dystrophy (DMD) treatable ...
Golodirsen
Golodirsen is used to treat Duchenne muscular dystrophy (DMD) in children and young adults with a ...
Givinostat
Givinostat (Duvyzat) is used to treat Duchenne muscular dystrophy (DMD) to delay symptoms and ...
Eteplirsen
Eteplirsen is used for Duchenne Muscular Dystrophy (DMD) in children and young adults with a gene ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.